CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

Regulators have also imposed $160,000 in fines on Cigna's Express Scripts unit; $66,000 in fines on Rightway PBM Services; ...

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...

Alleging that it was the true “architect” of West Virginia’s substance use disorder crisis first fueled by prescription ...

Alleging that it was the true “architect” of West Virginia’s substance use disorder crisis first fueled by prescription ...

CVS Health will not cover Gilead's Yeztugo, generic name lenacapavir (LEN), citing "clinical, financial, and regulatory ...

The store at 1515 W. State St. near downtown was planned to be sold to CVS Pharmacy as part of Rite Aid’s bankruptcy ...

CVS Health, which operates the largest U.S. pharmacy benefit manager, will not add Gilead Sciences’ new HIV prevention drug ...

A federal judge has ordered CVS Caremark to pay nearly $290 million in damages after determining the pharmacy benefit manager overbilled Medicare for prescription drugs, according to court documents ...

Notably, the case came from a whistleblower lawsuit filed by Sarah Behnke, a former Medicare Part D actuary at Aetna, who ...

Chief Judge Mitchell Goldberg tripled to $285 million the damages he had ordered CVS Caremark to pay in June, citing the ...